Androgen receptor

Caris Life Sciences to Present Research at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Tuesday, January 23, 2024
Neutrophil, PST, Research, Overalls, Prostate cancer, Androgen receptor, University, Cancer, NCI, Prognosis, Metastasis, FACP, Transcriptome, MHC, Abstract, Diagnosis, Medicine, MYC, NK, Neoplasm, MAPK, DNA, Survival, HSD3B1, Disease, Drug development, ADT, E2F, Liver, PIM, Urachal cancer, Lung, POA, Physician, Renal cell carcinoma, PCA, B cell, Poster, RCC, Escape Room, AI, Immunotherapy, Recurrence, MBA, Prostate, Phenotype, PIM1, Gene expression, IL-6, Huntsman Cancer Institute, Patient, MD, Metadata, ASCO, WSP, C7, Society, PSA, FDA, NEPC, Vaccine

IRVING, Texas, Jan. 23, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • That's a major focus of the wide array of research Caris and our POA collaborators will proudly present at this year's ASCO GU."
  • The research is a collaboration with the Huntsman Cancer Institute at the University of Utah and other POA members.
  • Caris will present additional data from studies demonstrating the critical role of comprehensive molecular profiling in the treatment of genitourinary cancers.
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer

Retrieved on: 
Thursday, February 23, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Clinical trial, Death, AR, Safety, Intelligence, IND, Drug discovery, Patient, National Medical Products Administration, Cancer, Androgen receptor, Incidence, NMPA, Pharmacokinetics, Pharmaceutical industry

Accutar Biotechnology, Inc ., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.

Key Points: 
  • Accutar Biotechnology, Inc ., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.
  • “The initiation of this study marks the second program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0176 Phase 1 study in the US and the IND clearance by the China National Medical Products Administration (NMPA) last year,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “Prostate cancer is one of the most common cancers among men in China, and the increase in its incidence and death ranks highest in China.
  • We look forward to accelerating the development of AC0176 globally to bring transformative medicines to patients worldwide.”
    The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0176 treatment in Chinese patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
  • Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05673109).

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer

Retrieved on: 
Friday, August 19, 2022
Technology, FDA, Men, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Oncology, Artificial Intelligence, Safety, Pharmacokinetics, IND, Biotechnology, Androgen receptor, National Medical Products Administration, Man, Incidence, AR, Intelligence, MCRPC, Prostate cancer, NMPA, Cancer, Drug discovery, Patient, Pharmaceutical industry

Accutar Biotechnology, Inc. , a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the companys investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic Castration Resistant Prostate Cancer (mCRPC).

Key Points: 
  • Accutar Biotechnology, Inc. , a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the companys investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
  • AC0176 is an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.
  • Prostate cancer is one of the most common cancers among men in China, and the speed of increase in its incidence and death rates ranks highest in China.
  • AC0176 is an investigational orally bioavailable, chimeric degrader of androgen receptor (AR) for the potential treatment of prostate cancers.

Caris Life Sciences to Present at the 2021 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 7, 2021
Twitter, Precision medicine, Technology, Disease, Duke Cancer Institute, CCND1, Breast cancer, Androgen receptor, Wilms' tumor, TMB, Diagnosis, USC Norris Comprehensive Cancer Center, POA, Poster, Blood, Physician, Metastasis, ICI, Drug development, FGF4, Patient, Biomarker, Alvin J. Siteman Cancer Center, NCI, TME, Brown University, Tumor microenvironment, Artificial intelligence, Biopsy, MSI-H, CNA, Science, CBFB, American Securities, DNA, Cancer, FGF19, MBC, Biology, Research, IHC, NGS, KMT2D, Brain, Exome, Bone, Protein, Mutation, Senior, Triple-negative breast cancer, RNA, Pharmaceutical industry, Medical imaging, Dentistry

IRVING, Texas, Dec. 7, 2021 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that it will present results at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer.

Key Points: 
  • IRVING, Texas, Dec. 7, 2021 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that it will present results at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer.
  • Relationships between breast cancer metastases site and mutations detected by DNA next-generation sequencing were investigated using 12,464 breast cancer samples using Caris' Next-Generation Sequencing (NGS) technology.
  • Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer.
  • Co-occurring biomarkers within TMB-H breast cancer warrant evaluation in prospective cohorts for response or resistance to ICI to help develop composite biomarkers in breast cancer.

Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology

Retrieved on: 
Thursday, September 9, 2021

LEUVEN, Belgium, Sept. 9, 2021 /PRNewswire/--Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer.

Key Points: 
  • LEUVEN, Belgium, Sept. 9, 2021 /PRNewswire/--Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer.
  • This alliance is an expansion of an existing collaboration with Ionis on the FLAME discovery engine, following Flamingo's Series A financing in 2020.
  • In connection with the alliance, Rob MacLeod, Ph.D.,VP, Oncology Research & Development of Ionis, will serve as Chief Scientific Officer of Flamingo.
  • Flamingo has a discovery alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV.

2021 Geographic Atrophy (Ophthalmology) Drugs in Development Report - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Pharmaceutical, Branches of biology, Health sciences, Anatomy, Gross pathology, Anatomical pathology, Atrophy, Androgen receptor, Geographic atrophy, Mechanism of action

The "Geographic Atrophy (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Geographic Atrophy (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Geographic Atrophy (Ophthalmology) therapeutics and enlists all their major and minor projects.

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Organ systems, Biology, Androgen receptor, Prostate cancer, Agonist, Psoriasis

The multiple ascending dose part of the phase 1 trial with 14-day daily dosing in healthy volunteers is ongoing and progressing.

Key Points: 
  • The multiple ascending dose part of the phase 1 trial with 14-day daily dosing in healthy volunteers is ongoing and progressing.
  • Recently published third-party studies[3] have shown that ROR plays an important pro-tumor role by driving expression of the androgen receptor (AR), leading to tumor growth.
  • Immunic's management team will host a virtual R&D Day today, July 12, 2021, at4:00 p.m. Eastern Time to discussthe updates on the preclinical and clinical development of the company's IMU-935 program.
  • IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome.

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress

Retrieved on: 
Monday, June 28, 2021
Anatomy, Organ systems, Prostate cancer, Branches of biology, Management of prostate cancer, Prostate, Androgen receptor, Androgen deprivation therapy, James L. Gulley

Abstract # P0859: Sabizabulin (VERU-111), an oral cytoskeleton disruptor, to treat men with metastatic castration resistant prostate cancer who progressed on an androgen receptor targeting agent.

Key Points: 
  • Abstract # P0859: Sabizabulin (VERU-111), an oral cytoskeleton disruptor, to treat men with metastatic castration resistant prostate cancer who progressed on an androgen receptor targeting agent.
  • Veru Inc.is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer.
  • Verus prostate cancer pipeline includes: sabizabulin, an oral, first-in-class, new chemical entity that targets the cytoskeleton disruptor which in prostate cancer also disrupts the transport of the androgen receptor.
  • A Phase 3 VERACITY clinical trial evaluating the efficacy and safety of sabizabulin in approximately 245 men for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer is enrolling.

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer

Retrieved on: 
Friday, June 25, 2021
Organ systems, Clinical medicine, Chemical compounds, Prostate cancer, Nonsteroidal antiandrogens, Progonadotropins, Histopathology, Androgen receptor, Enzalutamide, James L. Gulley

The Phase 3 VERACITY clinical trial is an open label, randomized (2:1), multicenter registration study to evaluate the efficacy and safety of sabizabulin 32mg oral daily dosing versus an alternative androgen receptor targeting agent for the treatment of chemotherapy nave men with metastatic castration resistant prostate cancer who have progressed on at least one androgen receptor targeting agent.

Key Points: 
  • The Phase 3 VERACITY clinical trial is an open label, randomized (2:1), multicenter registration study to evaluate the efficacy and safety of sabizabulin 32mg oral daily dosing versus an alternative androgen receptor targeting agent for the treatment of chemotherapy nave men with metastatic castration resistant prostate cancer who have progressed on at least one androgen receptor targeting agent.
  • Unfortunately, advanced prostate cancer patients receiving androgen receptor targeting agents in combination with standard ADT will eventually have tumor progression.
  • Verus prostate cancer pipeline includes: sabizabulin, an oral, first-in-class, new chemical entity that targets the cytoskeleton disruptor which in prostate cancer also disrupts the transport of the androgen receptor.
  • A Phase 3 VERACITY clinical trial evaluating the efficacy and safety of sabizabulin in approximately 245 men for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer is enrolling.

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) on Cutting Edge of Billion-Dollar Edtech Market

Retrieved on: 
Friday, June 18, 2021
OTC Markets Group, Androgen receptor

With AR, computer-generated objects are seen on a screen in real time, a technique that helps students learn in a more interactive and engaging environment.

Key Points: 
  • With AR, computer-generated objects are seen on a screen in real time, a technique that helps students learn in a more interactive and engaging environment.
  • Grand View sees the global AR market growing at a spectacular 43.8% compound annual growth rate to $340.2 billion by 2028.
  • Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB:NEXCF) is on the cutting edge of the markets as a developer and operator of AR platforms that transports 3D product visualizations, human holograms and 360 portals.
  • By cutting through the overload of information in todays market, NNW brings its clients unparalleled visibility, recognition and brand awareness.